Publications

The Lancet. Oncology

Biomarkers for outcome upon MAPK inhibition in melanoma.

01-12-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

15-11-2016

Cell metabolism

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

08-11-2016

European journal of cancer (Oxford, England : 1990)

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

01-11-2016

Journal of clinical pharmacology

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

01-10-2016

Cancer immunology, immunotherapy : CII

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.

01-09-2016

European journal of cancer (Oxford, England : 1990)

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

01-09-2016

World journal of urology

Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome.

01-08-2016

World journal of urology

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.

01-08-2016

Nederlands tijdschrift voor geneeskunde

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

22-07-2016

Cell reports

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

28-06-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.

15-06-2016

Annals of oncology : official journal of the European Society for Medical Oncology

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

01-06-2016

Cancer immunology, immunotherapy : CII

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

01-06-2016

Science (New York, N.Y.)

CANCER IMMUNOLOGY. The "cancer immunogram".

06-05-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

01-05-2016

Science (New York, N.Y.)

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

09-10-2015

Cancer immunology, immunotherapy : CII

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

01-10-2015

Molecular therapy : the journal of the American Society of Gene Therapy

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

01-09-2015

EMBO molecular medicine

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

01-09-2015

The Lancet. Oncology

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

01-08-2015

Seminars in oncology

Toxicity patterns with immunomodulating antibodies and their combinations.

01-06-2015

European journal of cancer (Oxford, England : 1990)

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

01-03-2015

International immunology

Therapeutic use of anti-CTLA-4 antibodies.

01-01-2015

Nature communications

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

15-12-2014

Science translational medicine

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

17-09-2014

Cancer immunology, immunotherapy : CII

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

01-05-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

The Lancet. Oncology

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

01-04-2014

Current opinion in oncology

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.

01-03-2014

OncoTargets and therapy

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.

19-12-2013

European journal of clinical pharmacology

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

01-12-2013

Nature medicine

High-throughput identification of antigen-specific TCRs by TCR gene capture.

01-11-2013

Acta oncologica (Stockholm, Sweden)

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

01-11-2013

Practical neurology

Neurological immune-related adverse events of ipilimumab.

01-08-2013

Cancer immunology, immunotherapy : CII

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

01-03-2013

The American journal of pathology

Targeting BRAFV600E in an inducible murine model of melanoma.

01-09-2012

Oncoimmunology

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.

01-08-2012

Current oncology reports

Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?

01-06-2012

European journal of immunology

Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.

01-03-2012

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

10-01-2012

Melanoma research

Expression of the embryological morphogen Nodal in stage III/IV melanoma.

01-12-2011

Urology

A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.

01-10-2011

Journal of analytical toxicology

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

01-10-2011

Cancer immunology, immunotherapy : CII

Combination of targeted therapy and immunotherapy in melanoma.

01-10-2011

Current oncology reports

Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities.

01-06-2011

Cancer

Overall survival and PD-L1 expression in metastasized malignant melanoma.

15-05-2011

Annals of oncology : official journal of the European Society for Medical Oncology

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.

01-05-2011

Cancer immunology, immunotherapy : CII

RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.

01-08-2010

World journal of urology

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

01-08-2009